Differential inhibition of rat liver DNA polymerases in vitro by direct-acting carcinogens and the protective effect of a thiol reducing agent

Altered DNA ligase I activity in Bloom's syndrome cells

Cells from patients with Bloom's syndrome, a rare disease associated with increased cancer frequency, exhibit cytological abnormalities. These include increased numbers of homologous chromatid interchange figures and sister-chromatid exchanges, together with abnormally slow replicon-fork progression and retarded rate of DNA-chain maturation, and suggest that the primary defect in this recessive disorder affects S-phase DNA replication. DNA ligases and DNA polymerases have long been prime candidates for abnormality in Bloom's syndrome, but various studies of DNA polymerases in Bloom's syndrome cells have disclosed no abnormalities. Evidence is presented here, as in the accompanying paper from a different laboratory, for the existence in Bloom's syndrome of an abnormality of the DNA ligase involved in semi-conservative DNA replication.

Induction of DNA damage and repair synthesis in freshly isolated rat hepatocytes by the proallatocidin precocene II

The proallatocidin precocene II (6,7-dimethoxy-2,2-dimethyl-2H-benzo-[b]pyran) has previously been shown to induce centrolobular liver necrosis. Here we have examined the ability of precocene II to produce DNA damage in suspensions of freshly isolated rat hepatocytes using the alkaline elution technique with N-methyl-N'-nitro-N-nitrosoguanidine as a positive control. At concentrations (10(-4)-10(-5) M) which did not induce cytotoxicity as judged by the leakage of glutamic-oxaloacetic transaminase, precocene II was capable of producing DNA single-strand breaks. In addition, a dose-dependent DNA repair synthesis (unscheduled DNA synthesis, UDS) was detected in hepatocytes exposed to precocene II. The induction of UDS was measured by incorporation of [3H]thymidine into purified hepatic DNA via a membrane filter retention method and liquid scintillation counting. Hence, results obtained in the present study indicate the potential genotoxicity of precocene II and the utility of DNA damage and repair assays in genetic toxicology.

Inhibition of DNA and RNA synthesis in rat liver nuclei by oncogenic and non-oncogenic beta-blockers

The beta-blocker DL-1-(2-nitro-3-methylphenoxy)-3-tert-butylaminopropan-2-ol (ZAMI 1305), hepatocarcinogenic to the female rat, and the non-oncogenic beta-blockers DL-1-(2-nitro-5-methylphenoxy)-3-tert-butylaminopropan-2-ol (ZAMI 1327), DL-propranolol, and DL-atenolol were studied for their capacity to interfere with hepatic DNA and RNA synthesis. These moieties inhibit DNA and RNA synthesis, in a dose-dependent fashion, when added in vitro to nuclei isolated from the liver of male or female rats. The inhibition is due to a decrease of the initial rate of synthesis and of the total amount of labeled precursor incorporated into the growing chains. When administered in vivo both the oncogenic ZAMI 1305 and its non-oncogenic isomer ZAMI 1327 inhibit hepatic DNA and RNA synthesis in female rats, as evaluated by the determination of nucleic acids synthesis in liver nuclei isolated from female rats 5 and 15 min after the injection of the drug. No influence on hepatic DNA and RNA synthesis is observed when the molecules are administered to male rats. The in vivo administration of DL-propranolol causes an increase of hepatic DNA and RNA synthesis in male rats, while it is uneffective in female rats.

Potentiation of dimethylnitrosamine genotoxicity in rat hepatocytes isolated following ethanol treatment in vivo

Unscheduled DNA synthesis (UDS), following exposure to dimethylnitrosamine (DMN), was potentiated in cultured hepatocytes isolated following treatment of rats for 14 or 28 days with 20% ethanol/5% sucrose solution. Ethanol treatment was associated with increased UDS, a concomitant increase in hepatic microsomal protein concentration and DMN N-demethylase activity. Increased aniline hydroxylase activity of hepatic microsomes from ethanol-treated rats preceded the measured increase in microsomal protein content or DMN metabolism. The increase in metabolism of DMN in vitro and potentiation of DMN-induced UDS associated with ethanol treatment may contribute to a synergistic effect of ethanol on DMN hepatotoxicity and carcinogenicity. In contrast, ethanol pretreatment did not increase the cytotoxicity of DMN as characterized by enzyme release.

Optical isomers of the hepatocarcinogenic beta-blocker ZAMI 1305: influence on nucleic acids synthesis and DNA integrity

The influence on nucleic acids synthesis and DNA integrity of the D-isomer and of the DL-racemic form of the oncogenic beta-blocker 1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305) and of the non-oncogenic beta-blocker propranolol was tested in vitro and in vivo. Both D- and DL-ZAMI 1305, when added in vitro to nuclei isolated from rat liver, cause inhibition of DNA and RNA synthesis and DNA fragmentation, as evaluated by alkaline sucrose gradient analysis, in a similar dose-dependent fashion. D- and DL-ZAMI 1305 also inhibit to a similar extent the activity of DNA polymerase alpha and beta from regenerating rat liver. When administered in vivo to female rats both D and DL-ZAMI 1305 cause a dose-dependent fragmentation of liver DNA. The D-isomer and DL-racemic form of the non-oncogenic beta-blocker propranolol inhibit DNA and RNA synthesis and cause DNA fragmentation when added in vitro to isolated liver nuclei, being instead without effect when administered in vivo.

In vitro inhibition of rat liver DNA polymerases α and β by β-blockers

The activity of DNA polymerases α and β, isolated from regenerating rat liver, is inhibited, in a dose-dependent fashion, by the oncogenic β-blocker DL-I-(2-nitro-3-methyl-phenoxy) - 3-tert-butylamino-propan-2-ol (ZAM[ 1305) and by non-oncogenic β-blockers DL-l-(2-nitro-5-methyl-phenoxy-3-tert-butylamino-propan-2-ol (ZAMI 1327) and DL-propranolol. The inhibition is due to a reversible interaction of the g-blockers with the two DNA polymerases. The interaction does not involve the template-DNA-binding site or the deoxynucleotide-binding site of the enzyme molecule. The degree of inhibition appears to be related to the hydrophobicity of the aromatic moiety and to the length and/or hydrophilicity of the aliphatic chain of the β-blocker molecule. These results may explain the transient in vivo inhibition of hepatic DNA synthesis observed in female rats treated with ZAMI 1305 or ZAMI 1327.

Inhibition in vitro of yeast DNA polymerase I activity by beta-blockers

The activity of DNA polymerase I from Saccharomyces cerevisiae is inhibited, in a dose-dependent fashion, by the oncogenic beta-blocker 1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305) and by the non-oncogenic beta-blockers 1-(2-nitro-5-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1327), atenolol, and propranolol, the latter having the highest inhibiting activity. The inhibition is due to an interaction of the beta-blockers with the free enzyme and with the enzyme-DNA complex. The degree of inhibition is directly related to the hydrophobicity of the aromatic moiety and to the length and hydrophilicity of the aliphatic chain of the inhibitor. No relation seems to exist between the in vitro inhibition of yeast DNA polymerase I by beta-blockers and their oncogenic activity.

Presidential address. Recent concepts of initiation and promotion in carcinogenesis

Images